Telangiectasis Clinical Trial
Official title:
A Clinical Evaluation of the Treatment of Lower Extremity Spider Veins Using a Dual Wavelength Laser Emitting 532 nm and 1064 nm Laser Energy
The purpose of this study is to evaluate the safety and effectiveness of a new laser for the removal of unsightly spider veins on the legs. The device used in this study is the Cutera Excel V laser, which is a dual wavelength 532 nm potassium titanyl phosphate (KTP) and 1064 nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser. The Excel V laser has received 510(k) clearance from the FDA, which means the FDA has approved the laser for dermatological and vascular conditions, like spider veins.
Each subject will receive 532 nm KTP laser treatment for their lower extremity spider veins in at least 2, and up to 4, separate areas. Subjects will receive 2 laser treatments spaced 12 weeks apart. Subjects will be followed for 24 weeks (12 weeks after the final laser treatment). Efficacy will be evaluated by blinded independent physician assessment of improvement in treated spider veins using digital photographs taken at baseline and the final follow-up visit by a third-party medical photography service. In addition, efficacy will be evaluated by the Investigator's mean global assessment of improvement and the subject's mean assessment of improvement. Safety will be evaluated by continuous monitoring of adverse events (AEs) and measuring pain associated with laser treatment. ;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00406380 -
Effect of Avastin in Juxtafoveal Telangiectasias
|
Phase 3 | |
Completed |
NCT00005386 -
Biobehavioral Determinants of Obesity in Black Women
|
N/A | |
Completed |
NCT00005392 -
Epidemiology of Venous Disease
|
N/A | |
Completed |
NCT01205035 -
High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
|
Phase 2 | |
Completed |
NCT00725244 -
Trial of Endoscopy Bipolar and Argon of Chronic Rectal Bleeding From Radiation Telangiectasias
|
Phase 4 | |
Withdrawn |
NCT02090517 -
Laser Therapy Versus Electrosurgery For Nasal Telangiectasias
|
N/A | |
Completed |
NCT02657252 -
Polidocanol Versus Glucose Treatment of Telangiectasia Trial
|
Phase 4 | |
Completed |
NCT02104271 -
Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial.
|
Phase 2 | |
Completed |
NCT00451763 -
Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia
|
Phase 3 | |
Completed |
NCT05860439 -
Lower Limb Sclerotherapy of Reticular Veins and Telangiectasias
|
||
Recruiting |
NCT00206921 -
Pulsed Dye Laser and Intense Pulsed Light (IPL) for the Treatment of Telangiectasia and Skin Redness
|
N/A |